Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders

 Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders

Takeda Receives the US FDA Advisory Committee’s Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients

Shots:

  • Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development stages. Selecta is also eligible to receive royalties on future commercial sales
  • The collaboration will utilize Selecta’s ImmTOR platform that accelerates transgene expression and addresses AAV vector immunogenicity to deliver transformative therapies for two indications
  • ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of gene therapies, restore the body’s natural self-tolerance in autoimmune diseases & can induce tolerance to highly immunogenic proteins

Click here to read full press release/ article | Ref: Selecta | Image: Takeda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post